[three_fourth]
This is an open Member’s only discussion to debate our acceptance of sponsorship from Valeant Pharmaceuticals.
A few of the issues raised include their advertising practices for Jublia:
- Ad campaigns which they do not mention that they are from Jublia.
- Psychological shaming strategies in their ads.
- Representations of efficacy which are per toe not per patient… so even a 15% success rate (vs placebo for complete cure) represents a failure rate of 85% . This is x2 if 2 toes are treated… i.e. 170% chance that 1 of two toes will not be cured.
- I have attached an article about the economics of this medication.
- Does this product fall below your standard of care?
Concerns were also raised about their predatory pricing of other medications such as Syprine – a drug which used to be dollars a pill until Valeant purchased it and without any new research increased the price to $300,000 per year. This is not a type error: Many references include https://www.bloomberg.com/view/articles/2017-04-18/valeant-drug-company-benevolence-and-the-silence-of-the-sick.
Netflix also has a one-hour documentary on Valeant. Dirty Money Season 1 Episode 3: “Drug Short”.
Respectfully submitted by Dr. Adam Zanbilowicz, DPM (BC)
Please provide your comments, concerns, feedback on this issue. Please scroll down to add your comment.
[/three_fourth]
[one_fourth]
[do_widget id=widget_mfn_menu-13][do_widget id=widget_mfn_menu-12]
[/one_fourth]
I am looking forward to reading our members comments on this topic
I would like our membership to engage Dr. Zanbilowicz on this topic. I have viewed the documentary and can see some of his concern. I am wondering if our small organization should sacrifice the sponsorship received from Valeant?
J Hill, DPM
Greetings.
I also agree that a line should be drawn where principle trumps profit/sponsorship. The difficulty is placing the line. I hope more members contribute to this discussion.
I am looking forward to more participation as well.
Testing to see if this starts a new thread.